[{"id":6211,"regimens":[{"id":11875,"duration":{"id":5873,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9077,"name":"Methylprednisolone","url":"cure-api2.ncats.io/v1/drugs/9077","rxNorm_id":null,"notes":null},"use_drug":[{"id":9003,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11875},{"id":9002,"answer":"In a novel combination with another drug","answer_other":"","regimen":11875}],"created":"2020-10-07T19:21:24.425361Z","updated":"2020-11-05T18:09:53.032101Z","dose":"","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6211},{"id":11876,"duration":{"id":5874,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":9004,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11876},{"id":9005,"answer":"In a novel combination with another drug","answer_other":"","regimen":11876}],"created":"2020-10-07T19:21:24.433515Z","updated":"2020-11-05T18:09:53.039397Z","dose":"400mg","frequency":"Once","route":"IV","severity":"Inpatient","severity_detail":"","comments":null,"report":6211},{"id":12469,"duration":null,"drug":{"id":7629,"name":"Enoxaparin","url":"cure-api2.ncats.io/v1/drugs/7629","rxNorm_id":null,"notes":null},"use_drug":[{"id":10105,"answer":"It was not used in a new way","answer_other":"","regimen":12469}],"created":"2020-11-05T18:09:53.061309Z","updated":"2020-11-05T18:09:53.069125Z","dose":"40mg","frequency":"BD","route":"SC","severity":null,"severity_detail":null,"comments":null,"report":6211},{"id":12470,"duration":null,"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":10106,"answer":"It was not used in a new way","answer_other":"","regimen":12470}],"created":"2020-11-05T18:09:53.065465Z","updated":"2020-11-05T18:09:53.069928Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6211}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":13880,"answer":"Clinical assessment","answer_other":"","report":6211},{"id":13881,"answer":"PCR","answer_other":"","report":6211}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4245,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6211}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-10-07T19:20:07.808320Z","updated":"2020-11-05T18:09:53.024053Z","title":"Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32374029,"doi":"10.1111/bjh.16792","article_url":"https://pubmed.ncbi.nlm.nih.gov/32374029/","pub_year":2020,"published_authors":"Griffin DO\r\nJensen A\r\nKhan M\r\nChin J\r\nChin K\r\nParnell R\r\nAwwad C\r\nPatel D","article_author_email":"dg2810@cumc.columbia.edu","journal":"British journal of haematology","abstract":"We present a case series of three patients with coronavirus disease 2019 (COVID‐19) who developed arterial vascular complications, one who developed an acute cerebrovascular accident, one who developed popliteal artery occlusion and one who developed both during their hospital course.","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hyperlipidemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"","severity":"ICU/Critical Care","prev_treatment":"","unusual":"The patient was found to have arterial thrombosis as a complication of COVID‐19.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patient presented with dyspnoea on day 14 of symptoms. His deep vein thrombosis (DVT) prophylaxis was increased to enoxaparin 40 mg subcutaneously twice a day. On day 23 of symptoms, the patient was noted to have left upper extremity weakness, code ‘stroke’ was called. Serial computed tomography (CT) showed a non‐haemorrhagic right parietal infarct and the patient was given tissue plasminogen activator (tPA). The patient’s neurological deficits resolved after tPA, but then he had an acute mental status change and was intubated to protect his airway. The patient was started on a full dose of enoxaparin for new onset rapid atrial fibrillation. On day 25 of symptoms, the patient developed a cool left lower extremity. Arterial Doppler showed no flow distal to the popliteal artery while on enoxaparin 1 mg/kg twice a day. He was transferred for surgical intervention, but did not undergo any surgical intervention and ultimately died.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[7629,9077,11408,10776]},{"id":6452,"regimens":[{"id":12581,"duration":{"id":6575,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5901,"name":"Amoxicillin","url":"cure-api2.ncats.io/v1/drugs/5901","rxNorm_id":null,"notes":null},"use_drug":[{"id":10436,"answer":"Other","answer_other":"Likely given for bacterial cover","regimen":12581}],"created":"2020-11-13T18:31:59.608650Z","updated":"2020-11-13T22:07:28.533612Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6452},{"id":12582,"duration":{"id":6576,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6772,"name":"Chloroquine","url":"cure-api2.ncats.io/v1/drugs/6772","rxNorm_id":null,"notes":null},"use_drug":[{"id":10373,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12582},{"id":10374,"answer":"In a novel combination with another drug","answer_other":"","regimen":12582}],"created":"2020-11-13T18:31:59.616416Z","updated":"2020-11-13T22:07:28.493232Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6452},{"id":12616,"duration":null,"drug":{"id":9229,"name":"Nadroparin","url":"cure-api2.ncats.io/v1/drugs/9229","rxNorm_id":null,"notes":null},"use_drug":[{"id":10437,"answer":"Other","answer_other":"For thrombosis prophylaxis","regimen":12616}],"created":"2020-11-13T22:07:28.516722Z","updated":"2020-11-13T22:07:28.534481Z","dose":"3800 IU, later increased to 5700 IU","frequency":"daily","route":"SC","severity":null,"severity_detail":null,"comments":null,"report":6452},{"id":12617,"duration":null,"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":10438,"answer":"It was not used in a new way","answer_other":"","regimen":12617},{"id":10439,"answer":"Other","answer_other":"For cerebral infarct","regimen":12617}],"created":"2020-11-13T22:07:28.520764Z","updated":"2020-11-13T22:07:28.535344Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6452},{"id":12618,"duration":null,"drug":{"id":6964,"name":"Clopidogrel","url":"cure-api2.ncats.io/v1/drugs/6964","rxNorm_id":null,"notes":null},"use_drug":[{"id":10440,"answer":"It was not used in a new way","answer_other":"","regimen":12618},{"id":10441,"answer":"Other","answer_other":"for secondary stroke prevention","regimen":12618}],"created":"2020-11-13T22:07:28.525145Z","updated":"2020-11-13T22:07:28.536171Z","dose":null,"frequency":"","route":"","severity":null,"severity_detail":null,"comments":null,"report":6452},{"id":12619,"duration":null,"drug":{"id":10749,"name":"Tinzaparin","url":"cure-api2.ncats.io/v1/drugs/10749","rxNorm_id":null,"notes":null},"use_drug":[{"id":10442,"answer":"It was not used in a new way","answer_other":"","regimen":12619},{"id":10443,"answer":"Other","answer_other":"Initiated after PE was diagnosed","regimen":12619}],"created":"2020-11-13T22:07:28.529363Z","updated":"2020-11-13T22:07:28.537078Z","dose":"18,000 IU","frequency":"daily","route":"sc","severity":null,"severity_detail":null,"comments":null,"report":6452}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8480,"answer":"Clinical assessment","answer_other":"","report":6452},{"id":8481,"answer":"Imaging","answer_other":"","report":6452}],"how_diagnosis":[{"id":14493,"answer":"Clinical assessment","answer_other":"","report":6452},{"id":14494,"answer":"PCR","answer_other":"","report":6452},{"id":14520,"answer":"Imaging","answer_other":"","report":6452}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4584,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6452}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-11-13T18:29:40.000455Z","updated":"2020-11-13T22:07:28.479001Z","title":"Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32386986,"doi":"10.1016/j.thromres.2020.04.046","article_url":"https://pubmed.ncbi.nlm.nih.gov/32386986/","pub_year":2020,"published_authors":"Brüggemann R\r\nGietema H\r\nJallah B\r\nTen Cate H\r\nStehouwer C\r\nSpaetgens B","article_author_email":"Author email could not be found.","journal":"Thrombosis research","abstract":"Hypercoagulability is a major contributor to COVID-19 related pulmonary complications\r\nCommonly used approaches may be insufficient to ameliorate the risk of thromboembolic events in patients with COVID-19\r\nEven when on thromboprophylaxis, it is crucial to remain vigilant for the occurrence of VTE in patients with COVID-19.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":null,"country_contracted":"Netherlands","country_treated":"Netherlands","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"peripheral arterial disease","pregnant":false,"unknown":false,"site_of_disease":"lungs","clinical_syndrome":"pneumonia, respiratory tract infection, pulmonary embolism","severity":"ICU/Critical Care","prev_treatment":"","unusual":"Arterial and venous thromboembolic disease in a patient with COVID-19","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient has a history of peripheral arterial disease. This patient received oxygen via nasal cannula, and prophylactic low molecular weigh heparin. They also received IV rt-PA and after 24 h clopidogrel initiated for secondary stroke prevention. CT pulmonary angiography revealed pulmonary embolism in the right pulmonary artery and bilateral (sub)segmental pulmonary embolism were found. CT-imaging of the brain (including CT-angiography and CT-perfusion) showed no brain haemorrhage or arterial occlusion, yet a defect right frontal with large mismatch between perfusion and vascular volume recordings, indicative of right frontal lobe infarction, was seen.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5901,6772,6964,9229,10749,11408]},{"id":6640,"regimens":[{"id":13268,"duration":{"id":7158,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11420,"name":"Low Molecular Weight Heparin","url":"cure-api2.ncats.io/v1/drugs/11420","rxNorm_id":null,"notes":null},"use_drug":[{"id":11692,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13268},{"id":11693,"answer":"In a novel combination with another drug","answer_other":"","regimen":13268},{"id":11979,"answer":"Other","answer_other":"For ARDS and COVID associated hypercoagulation","regimen":13268}],"created":"2020-12-01T22:45:30.257538Z","updated":"2020-12-07T14:58:30.569574Z","dose":null,"frequency":"Therapeutic Dosage","route":"","severity":"Inpatient","severity_detail":"Non-Invasive Ventilation","comments":null,"report":6640},{"id":13269,"duration":{"id":7159,"approximate_duration":"","dates_unknown":true},"drug":{"id":11421,"name":"Unfractionated Heparin","url":"cure-api2.ncats.io/v1/drugs/11421","rxNorm_id":null,"notes":null},"use_drug":[{"id":11694,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13269},{"id":11695,"answer":"In a novel combination with another drug","answer_other":"","regimen":13269},{"id":11980,"answer":"Other","answer_other":"For ARDS and COVID associated hypercoagulation","regimen":13269}],"created":"2020-12-01T22:45:30.265554Z","updated":"2020-12-07T14:58:30.570492Z","dose":"500 U/h, then 1000 IU/h","frequency":"","route":"","severity":"Inpatient","severity_detail":"Non-Invasive Ventilation","comments":null,"report":6640},{"id":13270,"duration":{"id":7160,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":11696,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13270},{"id":11697,"answer":"In a novel combination with another drug","answer_other":"","regimen":13270},{"id":11981,"answer":"Other","answer_other":"For ARDS and COVID associated hypercoagulation","regimen":13270}],"created":"2020-12-01T22:50:12.086943Z","updated":"2020-12-07T14:58:30.571310Z","dose":"2 mg/h, then 30mg over 15h","frequency":"","route":"","severity":"Inpatient","severity_detail":"Non-Invasive Ventilation","comments":null,"report":6640}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8710,"answer":"Clinical assessment","answer_other":"","report":6640},{"id":8711,"answer":"PCR","answer_other":"","report":6640}],"how_diagnosis":[{"id":14974,"answer":"Clinical assessment","answer_other":"","report":6640},{"id":14975,"answer":"Imaging","answer_other":"","report":6640},{"id":14976,"answer":"PCR","answer_other":"","report":6640}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4820,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6640}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-01T22:41:43.908971Z","updated":"2020-12-07T14:58:30.524381Z","title":"Successful use of tPA for thrombolysis in COVID related ARDS: a case series. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32617806,"doi":"10.1007/s11239-020-02208-2","article_url":"https://pubmed.ncbi.nlm.nih.gov/32617806/","pub_year":2020,"published_authors":"Goyal A\r\nSaigal S\r\nNiwariya Y\r\nSharma J\r\nSingh P","article_author_email":"abhishek.pulmed@aiimsbhopal.edu.in","journal":"Journal of thrombosis and thrombolysis","abstract":"We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO2 > 0.7(on NIV); PiO2/FiO2 ratio < 100 and D-dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19.          \r\n        Keywords:      \r\n                  Acute respiratory distress syndrome (ARDS); COVID19; Coagulopathy; Thrombolysis; Tissue plasminogen activator (tPA).","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"India","country_treated":"India","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pulmonary micro-thrombosis, Pneumonia, Dyspnoea","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Reason for shifting from LMWH to UFH was to have better control over bleeding episodes.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11420,11408,11421]},{"id":6641,"regimens":[{"id":13271,"duration":{"id":7161,"approximate_duration":"7 Days","dates_unknown":true},"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":11698,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13271},{"id":11699,"answer":"In a novel combination with another drug","answer_other":"","regimen":13271}],"created":"2020-12-01T23:00:10.065808Z","updated":"2020-12-28T19:10:08.442621Z","dose":"50mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6641},{"id":13272,"duration":{"id":7162,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8233,"name":"Heparin","url":"cure-api2.ncats.io/v1/drugs/8233","rxNorm_id":null,"notes":null},"use_drug":[{"id":11700,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13272},{"id":11701,"answer":"In a novel combination with another drug","answer_other":"","regimen":13272}],"created":"2020-12-01T23:00:10.073617Z","updated":"2020-12-28T19:10:08.448950Z","dose":"1000 IU/h","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6641}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8712,"answer":"Clinical assessment","answer_other":"","report":6641},{"id":8713,"answer":"PCR","answer_other":"","report":6641}],"how_diagnosis":[{"id":14977,"answer":"Clinical assessment","answer_other":"","report":6641},{"id":14978,"answer":"Imaging","answer_other":"","report":6641},{"id":14979,"answer":"PCR","answer_other":"","report":6641}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4821,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6641}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":624,"answer":"Asian","answer_other":""}],"created":"2020-12-01T22:58:50.635931Z","updated":"2020-12-28T19:10:08.434349Z","title":"Successful use of tPA for thrombolysis in COVID related ARDS: a case series. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32617806,"doi":"10.1007/s11239-020-02208-2","article_url":"https://pubmed.ncbi.nlm.nih.gov/32617806/","pub_year":2020,"published_authors":"Goyal A\r\nSaigal S\r\nNiwariya Y\r\nSharma J\r\nSingh P","article_author_email":"abhishek.pulmed@aiimsbhopal.edu.in","journal":"Journal of thrombosis and thrombolysis","abstract":"We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO2> 0.7(on NIV); PiO2/FiO2 ratio < 100 and D-dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19.          \r\n        Keywords:      \r\n                  Acute respiratory distress syndrome (ARDS); COVID19; Coagulopathy; Thrombolysis; Tissue plasminogen activator (tPA).","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"India","country_treated":"India","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Coronary Artery Disease","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia, pulmonary micro-thrombosis, vomiting","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"On presentation, her room air sPO2 was 52%. D-dimer and fibrinogen were 1787 ng/ml and 704 mg/dl respectively. Her P/F ratio was 90 on NIV (FiO2 was 0.75) after 1 day of ICU management and she was getting fatigued and intubation was imminent due to worsening dyspnoea. 2D echocardiography was normal. She was given 50 mg tPA over 3 h. After a gap of 3 h of stopping tPA, her heparin was started @ 1000 IU/h. Within few hours of starting tPA, her RR decreased from 45/min to 20/min and she was much comfortable. Her FiO2 remained stable at 0.6 for 2 days and then decreased to 0.40 on third day and 0.21 after 7 days of tPA infusion and she was discharged by 13th day after negative COVID19 PCR report.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8233,11408]},{"id":6642,"regimens":[{"id":13273,"duration":{"id":7163,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":11702,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13273},{"id":11703,"answer":"In a novel combination with another drug","answer_other":"","regimen":13273}],"created":"2020-12-01T23:08:53.227842Z","updated":"2020-12-01T23:15:08.260537Z","dose":"50mg","frequency":"Over 3 Hours","route":"","severity":"ICU/Critical Care","severity_detail":"High flow nasal canula","comments":null,"report":6642},{"id":13274,"duration":{"id":7164,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11421,"name":"Unfractionated Heparin","url":"cure-api2.ncats.io/v1/drugs/11421","rxNorm_id":null,"notes":null},"use_drug":[{"id":11704,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13274},{"id":11705,"answer":"In a novel combination with another drug","answer_other":"","regimen":13274}],"created":"2020-12-01T23:08:53.236024Z","updated":"2020-12-01T23:15:08.266999Z","dose":"1000 IU/h","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"High flow nasal canula","comments":null,"report":6642}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8714,"answer":"Clinical assessment","answer_other":"","report":6642},{"id":8715,"answer":"PCR","answer_other":"","report":6642}],"how_diagnosis":[{"id":14980,"answer":"Clinical assessment","answer_other":"","report":6642},{"id":14981,"answer":"Imaging","answer_other":"","report":6642},{"id":14982,"answer":"PCR","answer_other":"","report":6642}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4822,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6642}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-01T23:07:50.220582Z","updated":"2020-12-01T23:15:08.252762Z","title":"Successful use of tPA for thrombolysis in COVID related ARDS: a case series. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32617806,"doi":"10.1007/s11239-020-02208-2","article_url":"https://pubmed.ncbi.nlm.nih.gov/32617806/","pub_year":2020,"published_authors":"Goyal A\r\nSaigal S\r\nNiwariya Y\r\nSharma J\r\nSingh P","article_author_email":"abhishek.pulmed@aiimsbhopal.edu.in","journal":"Journal of thrombosis and thrombolysis","abstract":"We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO2> 0.7(on NIV); PiO2/FiO ratio < 100 and \r\n D dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19.          \r\n        Keywords:      \r\n                  Acute respiratory distress syndrome (ARDS); COVID19; Coagulopathy; Thrombolysis; Tissue plasminogen activator (tPA).","article_type":"Original","study_type":"Case Report","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"India","country_treated":"India","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Hypothyroid, Obese","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pulmonary micro-thrombosis, Pneumonia, fever, breathlessness, decreased appetite","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11408,11421]},{"id":6650,"regimens":[{"id":13294,"duration":{"id":7184,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11408,"name":"Tissue plasminogen activator","url":"cure-api2.ncats.io/v1/drugs/11408","rxNorm_id":19,"notes":""},"use_drug":[{"id":11755,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13294},{"id":11756,"answer":"In a novel combination with another drug","answer_other":"","regimen":13294}],"created":"2020-12-02T18:45:54.219889Z","updated":"2020-12-02T19:26:43.778382Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6650},{"id":13295,"duration":{"id":7185,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5998,"name":"Argatroban","url":"cure-api2.ncats.io/v1/drugs/5998","rxNorm_id":null,"notes":null},"use_drug":[{"id":11757,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13295},{"id":11758,"answer":"In a novel combination with another drug","answer_other":"","regimen":13295}],"created":"2020-12-02T18:45:54.228384Z","updated":"2020-12-02T19:26:43.784840Z","dose":"","frequency":"","route":"IV Drip","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6650},{"id":13296,"duration":{"id":7186,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10343,"name":"Sodium Chloride, Hypertonic","url":"cure-api2.ncats.io/v1/drugs/10343","rxNorm_id":null,"notes":null},"use_drug":[{"id":11759,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13296},{"id":11760,"answer":"In a novel combination with another drug","answer_other":"","regimen":13296}],"created":"2020-12-02T18:45:54.235048Z","updated":"2020-12-02T19:26:43.790768Z","dose":"3% Solution","frequency":"","route":"IV Drip","severity":"ICU/Critical Care","severity_detail":"Intubation and mechanical ventilation","comments":null,"report":6650}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8724,"answer":"Clinical assessment","answer_other":"","report":6650}],"how_diagnosis":[{"id":15004,"answer":"Clinical assessment","answer_other":"","report":6650},{"id":15005,"answer":"Imaging","answer_other":"","report":6650},{"id":15006,"answer":"PCR","answer_other":"","report":6650}],"author_username":"Paige Evans","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Nurse","author_affiliation":"None","author_country":"","outcome_computed":"Undetermined","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4834,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6650},{"id":4835,"answer":"Unusual disease presentation","answer_other":"","report":6650}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-12-02T18:43:40.712847Z","updated":"2020-12-02T19:26:43.770574Z","title":"Neurovascular Complications in COVID-19 Infection: Case Series. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32527844,"doi":"10.3174/ajnr.A6655","article_url":"https://pubmed.ncbi.nlm.nih.gov/32527844/","pub_year":2020,"published_authors":"Franceschi AM\r\nArora R\r\nWilson R\r\nGiliberto L\r\nLibman RB\r\nCastillo M","article_author_email":"afranceschi@northwell.edu","journal":"AJNR. American journal of neuroradiology","abstract":"We present a series of 10 hospitalized patients with confirmed coronavirus 2019 infections who developed severe neurovascular complications and discuss the possible reasons for these findings and their relationship to the novel Severe Acute Respiratory Syndrome coronavirus 2 infection.","article_type":"Original","study_type":"Case Report","number_of_patients":10,"article_patient_number":"3","full_text_available":true,"outcome":"Patient's condition was unchanged","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs, Brain","clinical_syndrome":"Severe acute hypoxic respiratory failure, septic shock, subacute infarctions in the right frontal, right parietal, and right parieto-occipital regions with edema and mass effect resulting in subfalcine herniation","severity":null,"prev_treatment":"","unusual":"Unusual clinical manifestation by severe neurological complications.","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"The patient remains in the neurologic ICU upon reporting. \r\n\r\nIn addition to tPA for suspected acute right MCA infarction the patient was placed on extracorporeal membrane oxygenation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5998,10343,11408]}]